The Effect of Consuming on Body Composition and Blood Biochemistry Index
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Neipu Township
-
Pingtung, Neipu Township, Taiwan, 91201
- National Pingtung University of Science and Technology
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female aged between 20 and 60 years old
- Body mass index (BMI) ≥ 24 (kg/m^2) or body fat mass: male > 25%, female > 30%
- Prohibitions on other nutritional supplements (probiotics and prebiotics) before two weeks of the study
- Abidance by the similar diet and exercise habits over the study.
Exclusion Criteria:
- Pregnant or breastfeeding woman
- Menopausal woman
- Diabetes mellitus
- Implementation in weight loss programs before a half year of this study
- Metabolic disorders
- Kidney diseases
- Liver diseases
- Cardiovascular diseases
- Nervous system diseases
- Gastrointestinal diseases
- Heavy drinking or constant drug use.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: OTHER
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: Experimental: weight loss program kit
weight loss program kit
|
weight loss program supplement
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The change of body fat mass
Time Frame: Change from Baseline body fat mass at 2 months
|
The body fat mass (kg) was assessed by InBody770.
|
Change from Baseline body fat mass at 2 months
|
|
The change of Triglyceride
Time Frame: Change from Baseline triglyceride at 2 months
|
Venous blood was sampled to measure concentrations of Triglyceride
|
Change from Baseline triglyceride at 2 months
|
|
The change of Total cholesterol
Time Frame: Change from Baseline total cholesterol at 2 months
|
Venous blood was sampled to measure concentrations of Total cholestrol
|
Change from Baseline total cholesterol at 2 months
|
|
The change of HDL-cholesterol
Time Frame: Change from Baseline HDL-cholesterol at 2 months
|
Venous blood was sampled to measure concentrations of HDL-cholestrol
|
Change from Baseline HDL-cholesterol at 2 months
|
|
The change of LDL-cholesterol
Time Frame: Change from Baseline LDL-cholesterol at 2 months
|
Venous blood was sampled to measure concentrations of LDL-cholestrol
|
Change from Baseline LDL-cholesterol at 2 months
|
|
Fecal microbiome analysis
Time Frame: Change from Baseline Fecal microbiome at 2 months
|
Firmicutes, Bacteroidetes, Lactobucillius, and A. muciniphila were quantified by quantitative PCR.
|
Change from Baseline Fecal microbiome at 2 months
|
|
The change of body mass index (BMI)
Time Frame: Change from Baseline body mass index at 2 months
|
BMI is a measurement of a person's leanness or corpulence based on their height and weight, and is intended to quantify tissue mass.The body mass index (BMI, kg/m^2) and body mass (kg) were assessed by InBody770.
|
Change from Baseline body mass index at 2 months
|
|
The change of body fat percentage
Time Frame: Change from Baseline body fat percentage at 2 months
|
The body fat percentage (%) was assessed by InBody770
|
Change from Baseline body fat percentage at 2 months
|
|
The change of visceral fat
Time Frame: Change from Baseline visceral fat at 2 months
|
The visceral fat (10 cm^2) was assessed by InBody770.
|
Change from Baseline visceral fat at 2 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The change of fasting glycemia
Time Frame: Change from Baseline fasting glycemia at 2 months
|
Venous blood was sampled to measure concentrations of fasting glycemia
|
Change from Baseline fasting glycemia at 2 months
|
|
The change of aspartate aminotransferase
Time Frame: Change from Baseline aspartate aminotransferase at 2 months
|
Venous blood was sampled to measure concentrations of aspartate aminotransferase
|
Change from Baseline aspartate aminotransferase at 2 months
|
|
The change of alanine aminotransferase
Time Frame: Change from Baseline alanine aminotransferase at 2 months
|
Venous blood was sampled to measure concentrations of alanine aminotransferase
|
Change from Baseline alanine aminotransferase at 2 months
|
|
The change of albumin
Time Frame: Change from Baseline albumin at 2 months
|
Venous blood was sampled to measure concentrations of albumin
|
Change from Baseline albumin at 2 months
|
|
The change of creatinine
Time Frame: Change from Baseline creatinine at 2 months
|
Venous blood was sampled to measure concentrations of creatine
|
Change from Baseline creatinine at 2 months
|
|
The change of uric acid
Time Frame: Change from Baseline uric acid at 2 months
|
Venous blood was sampled to measure concentrations of uric acid
|
Change from Baseline uric acid at 2 months
|
|
The change of white blood cell
Time Frame: Change from Baseline white blood cell at 2 months
|
Venous blood was sampled to measure concentrations of white blood cell
|
Change from Baseline white blood cell at 2 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
Other Study ID Numbers
- 20-039-A
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gut Microbiota
-
NCT05086458Recruiting
-
NCT03785860Completed
-
NCT04303481Completed
-
NCT06100549Completed
-
NCT04351841Completed
Clinical Trials on Fruit and vegetable solid drink
-
NCT00516620CompletedHypertension | Diabetes | Heart Disease
-
NCT05144750CompletedDiabetes Mellitus, Type 2 | Diabetes Mellitus | Poverty
-
NCT01616628CompletedFocus of the Study is on the Use of Incentives to Promote | Healthier Eating in Low-income Communities
-
NCT04036773Completed
-
NCT01366222Completed
-
NCT00064298Completed
-
NCT03567967CompletedCardiovascular Diseases